Xia Zheng, Chunxia Li, Jing Ai, Guili Dong, Man Long, Mingyi Li, Shilin Qiu, Yanni Huang, Guangjun Yang, Tao Zhang, Zhenhui Li
{"title":"No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer","authors":"Xia Zheng, Chunxia Li, Jing Ai, Guili Dong, Man Long, Mingyi Li, Shilin Qiu, Yanni Huang, Guangjun Yang, Tao Zhang, Zhenhui Li","doi":"10.1007/s12149-024-01927-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the survival benefit of preoperative bone scan in asymptomatic patients with early-stage non-small cell lung cancer (NSCLC).</p><h3>Methods</h3><p>This retrospective study included patients with radical resection for stage T1N0M0 NSCLC between March 2013 and December 2018. During postoperative follow-up, we monitored patient survival and the development of bone metastasis. We compared overall survival, bone metastasis-free survival, and recurrence-free survival in patients with or without preoperative bone scan. Propensity score matching and inverse probability of treatment weighting were used to minimize election bias.</p><h3>Results</h3><p>A total of 868 patients (58.19 ± 9.69 years; 415 men) were included in the study. Of 87.7% (761 of 868) underwent preoperative bone scan. In the multivariable analyses, bone scan did not improve overall survival (hazard ratio [HR] 1.49; 95% confidence intervals [CI] 0.91–2.42; <i>p</i> = 0.113), bone metastasis-free survival (HR 1.18; 95% CI 0.73–1.90; <i>p</i> = 0.551), and recurrence-free survival (HR 0.89; 95% CI 0.58–1.39; <i>p</i> = 0.618). Similar results were obtained after propensity score matching (overall survival [HR 1.28; 95% CI 0.74–2.23; <i>p</i> = 0.379], bone metastasis-free survival [HR 1.00; 95% CI 0.58–1.72; <i>p</i> = 0.997], and recurrence-free survival [HR 0.76; 95% CI 0.46–1.24; <i>p</i> = 0.270]) and inverse probability of treatment weighting.</p><h3>Conclusion</h3><p>There were no significant differences in overall survival, bone metastasis-free survival, and recurrence-free survival between asymptomatic patients with clinical stage IA NSCLC with or without preoperative bone scan.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"534 - 543"},"PeriodicalIF":2.5000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-01927-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To investigate the survival benefit of preoperative bone scan in asymptomatic patients with early-stage non-small cell lung cancer (NSCLC).
Methods
This retrospective study included patients with radical resection for stage T1N0M0 NSCLC between March 2013 and December 2018. During postoperative follow-up, we monitored patient survival and the development of bone metastasis. We compared overall survival, bone metastasis-free survival, and recurrence-free survival in patients with or without preoperative bone scan. Propensity score matching and inverse probability of treatment weighting were used to minimize election bias.
Results
A total of 868 patients (58.19 ± 9.69 years; 415 men) were included in the study. Of 87.7% (761 of 868) underwent preoperative bone scan. In the multivariable analyses, bone scan did not improve overall survival (hazard ratio [HR] 1.49; 95% confidence intervals [CI] 0.91–2.42; p = 0.113), bone metastasis-free survival (HR 1.18; 95% CI 0.73–1.90; p = 0.551), and recurrence-free survival (HR 0.89; 95% CI 0.58–1.39; p = 0.618). Similar results were obtained after propensity score matching (overall survival [HR 1.28; 95% CI 0.74–2.23; p = 0.379], bone metastasis-free survival [HR 1.00; 95% CI 0.58–1.72; p = 0.997], and recurrence-free survival [HR 0.76; 95% CI 0.46–1.24; p = 0.270]) and inverse probability of treatment weighting.
Conclusion
There were no significant differences in overall survival, bone metastasis-free survival, and recurrence-free survival between asymptomatic patients with clinical stage IA NSCLC with or without preoperative bone scan.
期刊介绍:
Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine.
The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.